Q BioMed Inc (OTCQB:QBIO) Chief Commercial Officer Kristin Keller tells Proactive the group has announced a supply contract with the US Department of Defense and Veterans Affairs (VA), which will make its cancer bone pain drug available to over 9 million VA beneficiaries. The biotech has inked a deal for Strontium89 to be included on the Federal Supply Schedule (FSS) for eligible patients.
The contract is for five years and Q BioMed is preparing to serve the VA and Department of Defense (DoD) with activities that include a VA sales force, formulary and market access, medical education, and marketing.